摘要
阿达木单抗是一种注射用的生物治疗药物,其结构特点表现为人肿瘤坏死因子(TNF)的人源化单克隆抗体。阿达木单抗已先后在国家食品药品监督管理总局获批治疗类风湿关节炎、强直性脊柱炎,于2020年3月将非感染性葡萄膜炎纳入适应症内。近年来,阿达木单抗在临床应用中的作用越来越广泛。本文中笔者就阿达木单抗在眼科相关疾病应用的最新进展进行综述。
Adalimumab is a one of biological agents for injection.Its structure is characterized by humanized monoclonal antibody against human tumor necrosis factor(TNF).Adalimumab has been approved by the State Food and Drug Administration for the treatment of rheumatoid arthritis and ankylosing spondylitis.Non infectious uveitis was included in the indication in March 2020.Adalimumab is more and more widely used in clinical application.In this paper,the latest development of adalimumab in ophthalmic diseases was reviewed.
作者
马嘉蹊
米倩倩
周义仁
王丹
Ma Jiaxi;Mi Qianqian;Zhou Yiren;Wang Dan(Changchun University of Traditional Chinese Medicine,Changchun 130021,China;Department of Ophthalmology,Jilin Province People′s Hospital;Department of Ophthalmology,Jilin Province People′s Hospital,Changchun 130021,China)
出处
《中华眼科医学杂志（电子版）》
2022年第6期377-381,共5页
Chinese Journal of Ophthalmologic Medicine(Electronic Edition)
基金
吉林省药物临床合理使用促进项目(Y202115)
关键词
阿达木单抗
抗人肿瘤坏死因子
临床应用
进展
Adalimumab
Anti human tumor necrosis factor
Clinical application
Progress
作者简介
通信作者:王丹,Email:303683604@qq.com;马嘉蹊,长春中医药大学2020级眼科硕士研究生;周义仁,长春中医药大学2019级眼科硕士研究生.
